Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

Shares of NERV opened at $2.17 on Tuesday. The stock has a market capitalization of $15.13 million, a PE ratio of -4.92 and a beta of 0.11. The company has a 50 day moving average price of $2.22 and a 200-day moving average price of $2.58. Minerva Neurosciences has a fifty-two week low of $2.06 and a fifty-two week high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.